Search

Your search keyword '"GLP-1"' showing total 7,585 results

Search Constraints

Start Over You searched for: Descriptor "GLP-1" Remove constraint Descriptor: "GLP-1"
7,585 results on '"GLP-1"'

Search Results

1. Potential Therapeutic Targets in Obesity, Sleep Apnea, Diabetes, and Fatty Liver Disease.

2. Acute nicotine intake increases feeding behavior through decreasing glucagon signaling in dependent male and female rats

3. Why does GLP‐1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP‐1 agonist alone in obese adults without type 2 diabetes?

4. Incredible Indolinedione Derivatives Nucleus in the Development of Anti‐Diabetic Drugs: Exploring the Mechanistic Studies, Design, and Structure‐Activity Relationship.

5. Finerenone attenuates downregulation of the kidney GLP-1 receptor and glucagon receptor and cardiac GIP receptor in mice with comorbid diabetes.

6. Incretin hormones and obesity.

7. TRPV4 couples with NCX1 to mediate glucose‐dependent glucagon‐like peptide‐1 release and improve glucose homeostasis.

8. The potential role of CGRP in synuclein-associated neurodegenerative disorders.

9. Mechanisms of Insulin Signaling as a Potential Therapeutic Method in Intestinal Diseases.

10. Comparative Effect of Insulin Resistance Reduction and Hormonal Alterations on Type 2 Diabetes Remission After Bariatric Surgery.

11. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) as treatment for nicotine cessation in psychiatric populations: a systematic review.

12. Annual Prize Lecture 2024: Endogenous physiological mechanisms as basis for the treatment of obesity and type 2 diabetes.

13. Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: Results from the SURMOUNT‐1 study.

14. Non‐clinical and first‐in‐human characterization of ECC5004/AZD5004, a novel once‐daily, oral small‐molecule GLP‐1 receptor agonist.

15. Tirzepatide Improves Early Dumping Syndrome and Glucose Nadir in Postbariatric Hypoglycemia After Sleeve Gastrectomy.

16. Sex‐specific growth and lifespan effects of germline removal in the dioecious nematode Caenorhabditis remanei.

17. The Therapeutic Potential of GLP-1 Receptor Agonists in the Management of Hidradenitis Suppurativa: A Systematic Review of Anti-Inflammatory and Metabolic Effects.

18. A review of the latest real‐world evidence studies in diabetic kidney disease: What have we learned about clinical practice and the clinical effectiveness of interventions?

19. Cardiovascular and non‐renal complications of chronic kidney disease: Managing risk.

20. Elucidating the role of weight loss and glycaemic control in patients with type 2 diabetes.

21. A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy.

22. Adherence to glucagon‐like peptide‐1 receptor agonist treatment in type 2 diabetes mellitus: A nationwide registry study.

23. Host or the Hosted? Effects of Non-Nutritive Sweeteners on Intestinal and Microbial Mechanisms of Glycemic Control.

24. Dipeptidyl peptidase IV inhibitors reduce hepatic fibrosis and lipid accumulation in rat intestinal failure-associated liver disease models.

25. Splenectomy prevents brain orexin, ghrelin, or oxytocin but not GLP‐1‐induced improvement of intestinal barrier function in rats.

26. The role of incretins in gestational diabetes: a case-control study on the impact of obesity.

27. Glycaemic outcomes in adults with type 2 diabetes over 34 weeks with the Omnipod® 5 automated insulin delivery system.

28. Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs.

29. The gut–brain axis in appetite, satiety, food intake, and eating behavior: Insights from animal models and human studies.

30. Initiating GLP-1 Therapy in Combination with FreeStyle Libre Provides Greater Benefit Compared with GLP-1 Therapy Alone.

31. Real‐world impact of adding a glucagon‐like peptide‐1 receptor agonist compared with basal insulin on metabolic targets in adults living with type 2 diabetes and chronic kidney disease already treated with a sodium‐glucose co‐transporter‐2 inhibitor: The Impact GLP‐1 CKD study

32. Correlation of body metrics, assessed with a portable scanning device, with established anthropometrics in people with obesity.

33. A Revolution in the Treatment of Obesity.

34. Effect of hypoxia on GLP-1 secretion – an in vitro study using enteroendocrine STC-1 -cells as a model.

35. Neuroprotective Effects of Bifidobacterium animalis subsp. lactis NJ241 in a Mouse Model of Parkinson's Disease: Implications for Gut Microbiota and PGC-1α.

36. Oral Trehalose Intake Modulates the Microbiota–Gut–Brain Axis and Is Neuroprotective in a Synucleinopathy Mouse Model.

37. The Impact of Gastrointestinal Hormones on Human Adipose Tissue Function.

38. Comparative Analysis of Resmetirom vs. FGF21 Analogs vs. GLP-1 Agonists in MASLD and MASH: Network Meta-Analysis of Clinical Trials.

39. Liraglutide Therapy in Obese Patients Alters Macrophage Phenotype and Decreases Their Tumor Necrosis Factor Alpha Release and Oxidative Stress Markers—A Pilot Study.

40. Post-Bariatric Hypoglycemia: an Impaired Metabolic Response to a Meal.

41. Anekomochi glutinous rice provides low postprandial glycemic response by enhanced insulin action via GLP-1 release and vagal afferents activation.

42. Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis.

43. Tirzepatide a novel anti diabetic molecule unfold dual action.

44. Efficacy and Safety of Liraglutide in Patients With an Ileal Pouch-Anal Anastomosis and Chronic High Bowel Frequency: A Placebo-Controlled, Crossover, Proof-of-Concept Study.

45. Differences in the levels of the appetite peptides ghrelin, peptide tyrosine tyrosine, and glucagon-like peptide-1 between obesity classes and lean controls.

46. Gut hormone stimulation as a therapeutic approach in oral peptide delivery.

47. Randomised comparison of intravenous and subcutaneous routes of glucagon‐like peptide‐1 administration for lowering plasma glucose in hyperglycaemic subjects with type 2 diabetes.

48. No association between semaglutide and postoperative pneumonia in people with diabetes undergoing elective surgery.

49. The first report of leukocytoclastic vasculitis induced by once-weekly subcutaneous semaglutide.

50. The Efficacy of GLP-1 Agonists in Treating Substance Use Disorder in Patients: A Scoping Review.

Catalog

Books, media, physical & digital resources